CETUXIMAB 100 mg/20 mL (Cetuxa)

CETUXIMAB 100 mg/20 mL (Cetuxa)

$400.00 $210.00
Prescription Required

Cetuximab 100 mg/20 mL (Cetuxa) is a targeted anticancer medicine used to treat EGFR-expressing colorectal cancer and head and neck squamous cell carcinoma. It is administered as an intravenous infusion under medical supervision. Cetuximab works by blocking signals that promote cancer cell growth and spread, helping improve treatment outcomes.

Generic name Cetuximab
Strength 100 mg
Manufacturer ALKEM LABORATORIES
Package size 1 vial of 20 ml
Used for Metastatic colorectal cancer and head and neck squamous cell carcinoma
Availability In Stock
Shipping to USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries.
Enquire via WhatsApp

Uses of Cetuximab 100 mg

  • Treatment of EGFR-expressing metastatic colorectal cancer
  • Treatment of head and neck squamous cell carcinoma
  • Used alone or with chemotherapy or radiation therapy
  • Helps slow tumour growth
  • Reduces cancer progression

Benefits

  • Targets cancer cells specifically
  • Slows tumour growth
  • Improves response to cancer treatment
  • Helps delay disease progression
  • Supports long-term cancer management

How Does Cetuximab 100 mg Work?

Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) on cancer cells. By blocking EGFR, it prevents signals that promote cancer cell growth and division, helping slow tumour growth and spread.

Side Effects

  • Acne-like skin rash
  • Infusion-related reactions
  • Fatigue
  • Diarrhoea
  • Nausea
  • Low magnesium levels
  • Fever
  • Dry skin
  • Itching
  • Mouth sores

Precautions

  • Administer only under medical supervision.
  • Inform your doctor about any history of allergies or heart disease.
  • Regular monitoring of electrolyte levels may be required.
  • Protect your skin from sunlight during treatment.
  • Report breathing difficulty or severe infusion reactions immediately.
  • Attend all scheduled follow-up appointments.
  • Do not stop treatment without consulting your doctor.

Author

Reviewed By

Dr. Neeru Mehta

Doctor of Medicine (MD) | Professional Interest in Oncology

Dr. Neeru Mehta holds a Doctor of Medicine (MD) degree and has a professional interest in oncology and cancer care. Her interests include cancer treatments, monitoring treatment progress, managing side effects and supportive care.

Enquire via WhatsApp